| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.49(B) |
| Last
Volume: |
1,548,181 |
Avg
Vol: |
2,440,013 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14.9 |
| Insider 6 Months : 16.6 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
77,148 |
336,706 |
542,969 |
981,371 |
| Total Sell Value |
$1,703,116 |
$7,468,007 |
$11,664,525 |
$19,365,156 |
| Total People Sold |
3 |
5 |
6 |
10 |
| Total Sell Transactions |
3 |
9 |
13 |
25 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morrissey Michael M |
President and CEO |
• • – |
2021-05-12 |
4 |
OE |
$4.20 |
$210,000 |
D/D |
50,000 |
541,813 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2021-05-11 |
4 |
S |
$25.01 |
$206,958 |
D/D |
(8,275) |
31,827 |
|
20% |
|
| Papadopoulos Stelios |
Director |
– • – |
2021-05-11 |
4 |
S |
$24.95 |
$518,794 |
D/D |
(20,770) |
1,288,127 |
|
20% |
|
| Papadopoulos Stelios |
Director |
– • – |
2021-05-11 |
4 |
OE |
$3.13 |
$512,400 |
D/D |
120,000 |
1,293,600 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2021-05-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
40,616 |
1,019,067 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-04-26 |
4 |
AS |
$25.00 |
$1,250,000 |
D/D |
(50,000) |
613,482 |
|
-18% |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-04-26 |
4 |
OE |
$1.70 |
$85,000 |
D/D |
50,000 |
663,482 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2021-04-26 |
4 |
AS |
$25.03 |
$191,855 |
D/D |
(7,665) |
297,392 |
|
-18% |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2021-04-26 |
4 |
AS |
$25.03 |
$450,540 |
D/D |
(18,000) |
628,248 |
|
-18% |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-04-01 |
4 |
AS |
$23.00 |
$1,150,000 |
D/D |
(50,000) |
613,482 |
|
-25% |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-04-01 |
4 |
OE |
$1.70 |
$85,000 |
D/D |
50,000 |
663,482 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-04-01 |
4 |
AS |
$22.96 |
$1,377,600 |
D/D |
(60,000) |
389,467 |
|
-25% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-04-01 |
4 |
OE |
$1.70 |
$102,000 |
D/D |
60,000 |
449,467 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2021-03-29 |
4 |
AS |
$22.64 |
$140,821 |
D/D |
(6,220) |
231,589 |
|
-22% |
|
| Wyszomierski Jack L |
Director |
– • – |
2021-03-29 |
4 |
OE |
$3.38 |
$135,200 |
D/D |
40,000 |
237,809 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2021-03-15 |
4 |
AS |
$23.60 |
$944,000 |
D/D |
(40,000) |
12,718 |
|
-31% |
|
| Garber Alan M |
Director |
– • – |
2021-03-15 |
4 |
OE |
$3.38 |
$135,200 |
D/D |
40,000 |
52,718 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
59,570 |
305,057 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
49,395 |
389,467 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
64,150 |
356,591 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
72,885 |
613,482 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
57,135 |
646,248 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-03-01 |
4 |
AS |
$22.11 |
$1,437,150 |
D/D |
(65,000) |
340,072 |
|
-19% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-03-01 |
4 |
OE |
$1.70 |
$110,500 |
D/D |
65,000 |
405,072 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2021-02-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
67,374 |
1,059,683 |
|
- |
|
985 Records found
|
|
Page 11 of 40 |
|
|
0.32 (1.51%) 
